Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 37, 2009, Pages 15714-15719

  Kidambi, Srivatsan ^a   Yarmush, Rubin S ^a   Novik, Eric ^b   Chao, Piyun ^b   Yarmush, Martin L ^a   Nahmias, Yaakov ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HREL Corporation   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Drug discovery; Liver metabolism; Tissue engineering

Indexed keywords

BUSPIRONE; CARBAMAZEPINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGOXIN; GLYCOPROTEIN P; METOPROLOL; MIDAZOLAM; NARINGENIN; OXYGEN; PHENAZONE; RIFAMPICIN; SILDENAFIL; TIMOLOL;

ADAPTATION; AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL METABOLISM; CELL POLARITY; COCULTURE; CONTROLLED STUDY; COST UTILITY ANALYSIS; CULTURE MEDIUM; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; DRUG TRANSPORT; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; LIVER CELL; LIVER CELL CULTURE; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL POLARITY; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, SERUM-FREE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; DRUG INTERACTIONS; ENDOTHELIAL CELLS; GENE EXPRESSION; HEPATOCYTES; HUMANS; MICE; OXYGEN; PHARMACEUTICAL PREPARATIONS; RATS; TISSUE ENGINEERING;

RATTUS;

EID: 70349466841     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906820106     Document Type: Article

References (44)

1. Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499.
2. Ballet F (1997) Hepatotoxicity in drug development: Detection, significance, and solutions. J Hepatol 26:26-36. (Pubitemid 127672114)
3. Pritchard JF, et al. (2003) Making better drugs: Decision gates in non-clinical drug development. Nat Rev Drug Discov 2:542-553.
4. Lau YY, Sapidou E, Cui X, White RE, Cheng K-C (2002) Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos 30:1446-1454. (Pubitemid 35397053)
5. Gebhardt R, et al. (2003) New hepatocyte in vitro systems for drug metabolism: Metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 35:145-213. (Pubitemid 37048295)
6. Yarmush ML, et al. (1992) Hepatic tissue engineering. Development of critical technologies. Ann N Y Acad Sci 665:238-252.
7. Nahmias Y, Berthiaume F, Yarmush ML (2006) Integration of technologies for hepatic tissue engineering. In Advances in Biochemical Engineering/ Biotechnology, eds Lee K, Kaplan D (Springer Berlin, Heidelberg), Vol 103, pp 309-329. (Pubitemid 44623303)
8. Bhatia SN, Balis UJ, Yarmush ML, Toner M (1999) Effect of cell-cell interactions in preservation of cellular phenotype: Cocultivation of hepatocytes and non parenchymal cells. FASEB J 13:1883-1900.
9. Dunn JC, Yarmush ML, Koebe HG, Tompkins RG (1989) Hepatocyte function and extracellular matrix geometry: Long-term culture in a sandwich configuration. FASEB J 3:174-177.
10. Dunn JC, Tompkins RG, Yarmush ML (1992) Hepatocytes in collagen sandwich: Evidence for transcriptional and translational regulation. J Cell Biol 116:1043-1053.
11. Landry J, Bernier D, Ouellet C, Goyette R, Marceau N (1985) Spheroidal aggregate culture of rat liver cells: Histotypic reorganization, biomatrix deposition, and maintenance of functional activities. J Cell Biol 101:914-923. (Pubitemid 16256845)
12. Bhatia SN, Yarmush ML, TonerM(1997) Controlling cell interactions by micropatterning in co-cultures: Hepatocytes and 3T3 fibroblasts. J Biomed Mater Res 34:189-199.
13. Morin O, Normand C (1986) Long-term maintenance of hepatocyte functional activity in co-culture: Requirements for sinusoidal endothelial cells and dexamethasone. J Cell Physiol 129:103-110. (Pubitemid 17178532)
14. Khetani SR, Bhatia SN (2007) Microscale culture of human liver cells for drug development. Nat Biotechnol:doi:10.1038/nbt1361.
15. Stevens KM (1965) Oxygen requirements for liver cells in vitro. Nature 206:199.
16. Nahmias Y, et al. (2006) A novel formulation of oxygen-carrying matrix enhances liver-specific function of cultured hepatocytes. FASEB J 20:2531-2533. (Pubitemid 44953770)
17. Balis UJ, et al. (1999) Oxygen consumption characteristics of porcine hepatocytes. Metab Eng 1:49-62.
18. Rotem A, Toner M, Tompkins RG, Yarmush ML (1992) Oxygen uptake rates in cultured rat hepatocytes. Biotechnol Bioeng 40:1286-1291.
19. Rotem A, et al. (1994) Oxygen is a factor determining in vitro tissue assembly: Effects on attachment and spreading of hepatocytes. Biotechnol Bioeng 43:654-660. (Pubitemid 24090712)
20. Tilles AW, Baskaran H, Roy P, Yarmush ML, TonerM(2001) Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor. Biotechnol Bioeng 73:379-389.
21. Yanagi K, Ohshima N (2001) Improvement of metabolic performance of cultured hepatocytes by high oxygen tension in the atmosphere. Artificial Organs 25:1-6. (Pubitemid 32113551)
22. Suleiman SA, Stevens JB (1987) The effect of oxygen tension on rat hepatocytes in short-term culture. In Vitro Cell Dev Biol 23:332-338.
23. Enat R, et al. (1984) Hepatocyte proliferation in vitro: Its dependence on the use of serum-free hormonally defined medium and substrata of extracellular matrix. Proc Natl Acad Sci USA 81:1411-1415.
24. Fujita M, et al. (1987) Glycosaminoglycans and proteoglycans induce gap junction expression and restore transcription of tissue-specific mRNAs in primary liver cultures Hepatology 7:1S-9S. (Pubitemid 17021989)
25. Turncliff RZ, Tian X, Brouwer KLR (2006) Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdrla/b in sandwich-cultured rat hepatocytes. Biochem Pharmacol 71:1520-1529.
26. Dam GB, et al. (2006) 3-O-Sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3. J Biol Chem 281:4654-4662.
27. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ (2008) Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: Implications for drug discovery. Nat Rev Drug Discov 7:84-99.
28. MacArthur JM, et al. (2007) Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 117:153-164.
29. Khetani SR, Szulgit G, Rio JAD, Barlow C, Bhatia SN (2004) Exploring interactions between rat hepatocytes and nonparenchymal cells using gene expression profiling. Hepatology 40:545-554. (Pubitemid 39265575)
30. Thummel KE, Shen DD, Isoherranen N, Smith HE (2005) Appendix II. Design and Optimization of Dosage Regimens: Pharmacokinetic Data. In Goodman&Gilman's The Pharmacological Basis of Therapeutics, ed Brunton LL (McGraw-Hill Professional), 11th Ed, pp 1984.
31. Lam JL, Benet LZ (2004) Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: Studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 32:1311-1316.
32. Benet LZ, Cumminsa CL, Wua CY (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9.
33. Custodio JM, Wu C-Y, Benet LZ (2008) Predicting drug disposition, absorption/ elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60:717-733.
34. Jurima-rometa M, Huanga HS, Beckb DJ, Li AP (1996) Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. Toxicol in Vitro 10:655-663.
35. Haehner T, Refaie MO, Müller-Enoch D (2004) Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system. Arzneimittelforschung 54:78-83.
36. Ho PC, Saville DJ, Wanwimolruk S (2001) Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 4:217-227.
37. Benet LZ (2005) There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol Interv 5:79-83.
38. Murray KF, Messner DJ, Kowdley KV (2006) Mechanisms of hepatocyte detoxification. In Physiology of the gastrointestinal tract, ed Johnson LR (Academic), 4 Ed. Vol 1, pp 1483-1504.
39. DiMasi JA (2002) The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 20:1-10.
40. DiMasi JA, Hansenb RW, Grabowskic HG (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185.
41. Uygun K, Matthew HWT, Huang Y (2007) Investigation of metabolic objectives in cultured hepatocytes. Biotechnol Bioeng 97:622-637. (Pubitemid 46848076)
42. Cho CH, et al. (2007) Oxygen uptake rates and liver-specific functions of hepatocyte and 3T3 fibroblast co-cultures. Biotechnol Bioeng 97:188-199.
43. Dunn JCY, Tompkins RG, Yarmush ML (1991) Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog 7:237-245.
44. Nahmias Y, Casali M, Barbe L, Berthiaume F, Yarmush ML (2006) Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. Hepatology 43:257-265. (Pubitemid 43303994)